Streetwise Expert Interviews

Pooya Hemami

How to Bargain Hunt for Hot Biotechs: Edison's Pooya Hemami

Every business day, Edison Investment Research Analyst Pooya Hemami scours the global markets for life science companies with upside flowing through their product pipelines. In this interview with The Life Sciences Report, Dr. Hemami tells us where to look for biotech bargains, including a few top-fliers and a handful of companies that have experienced temporary setbacks but are poised for blue sky.

(10/15/14) More >
Read More Streetwise Interviews

Griffin Securities' Keith Markey on the Promise of RNAi and Synthetic Biology

Through a combination of pipeline diversification, positive clinical data, and low-cost research and development strategies, many of the companies Markey mentions in this interview are able to mitigate the risk inherent in their technologies. (10/9/14) More >

Newsletter Briefs

"RXII's molecules are designed specifically to facilitate the uptake of their therapeutic payload." (10/8/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey More >

"The patent for CPMA builds RNN's intellectual property fortress." (10/7/14) Rexahn Pharmaceuticals Inc. - Sharon di Stefano, Seeking Alpha More >

"The share buyback shows MSLP's new nature, one of avoiding dilution." (10/6/14) MusclePharm Corp. - Paulo Santos, Seeking Alpha More >

"INO's Ebola vaccine was effective in 100% of two test animal sets." (10/2/14) Inovio Pharmaceuticals Inc. - Matthew Smith, Seeking Alpha More >

"We like IPD, which has an early detection device for lymphedema." (10/2/14) ImpediMed Ltd. - The Life Sciences Report Interview with Scott Power More >

"We are very positive on TLT's technology. It's very promising." (9/25/14) Theralase Technologies Inc. - The Life Sciences Report Interview with Anita Dushyanth More >

"RP is positioned to have significant upside." (9/24/14) RepliCel Life Sciences Inc. - Douglas Ehrman, Seeking Alpha More >

"Developments with MSLP continue to reinforce its original thesis." (9/22/14) MusclePharm Corp. - Paulo Santos, Seeking Alpha More >

Expert Analysis

"Expanding into advanced wound care is a main growth driver for MDXG." (10/13/14) MiMedx Group Inc. - Bruce Jackson, Lake Street Capital Markets More >

"We think THLD could become profitable in 2016 based on revenue from sales of TH-302." (10/13/14) Threshold Pharmaceuticals Inc. - George Zavoico, MLV & Co More >

"CUR's forward progress of the NSI-556 trial for SCI is welcome news." (10/13/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"CTH plans to complete three studies over Q4/14 and Q1/15." (10/9/14) Cynapsus Therapeutics Inc. - Ajay Tandon, SeeThruEquity More >

"Photos of RXII's treated patients showed significant improvement." (10/8/14) RXi Pharmaceuticals Corp. - Edward White, Laidlaw & Company More >

"We are increasing our price target for CTH." (10/2/14) Cynapsus Therapeutics Inc. - Nathan Cali, Noble Financial More >

"STEM launched the Pathway study, a Phase 2 trial in cervical SCI." (10/7/14) StemCells Inc. - Jason Kolbert, Maxim Group More >

"We are raising our price target for MDXG." (10/15/14) MiMedx Group Inc. - William Plovanic, Canaccord Genuity More >